Rithm’s Russell 1000 Defensive Upgrade and Dividend Plan Might Change The Case For Investing In RITM

Rithm Capital Corp.

Rithm Capital Corp.

RITM

0.00

  • Rithm Capital Corp. has recently been added to the Russell 1000 Defensive Index and Russell 1000 Value-Defensive Index, while also declaring a US$0.25 per-share common dividend for the second quarter of 2026 and confirming a suite of preferred stock dividends payable in July and August.
  • This combination of index inclusion and affirmed cash payouts highlights Rithm’s positioning as a value-oriented, income-focused real estate and credit manager that may draw more attention from benchmark-tracking institutional investors.
  • We’ll now examine how Rithm’s addition to defensive Russell indexes might influence its existing investment narrative around diversification and income.

The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Rithm Capital Investment Narrative Recap

To own Rithm Capital, you need to be comfortable with a real estate and credit manager that leans heavily on income generation and access to capital markets, while remaining exposed to interest rate cycles and competition in mortgage-related assets. The latest Russell 1000 Defensive and Value-Defensive index additions, alongside confirmed dividends, support its income-focused profile but do not materially change the near-term balance between the appeal of its yield and the risk of earnings pressure if funding costs stay elevated.

The reaffirmed US$0.25 per-share common dividend for the second quarter of 2026 stands out here, as it reinforces Rithm’s income identity at a time when its dividend is described as not well covered by earnings or free cash flow. For investors watching catalysts around income and diversification, this consistent payout track record sits alongside the new index inclusions, which could modestly broaden the shareholder base without resolving underlying sensitivity to funding conditions.

Yet for all the index recognition and cash payouts, the risk that persistently high funding costs strain a dividend that is not well covered is something investors should be aware of...

Rithm Capital's narrative projects $7.8 billion revenue and $1.2 billion earnings by 2029. This requires 22.7% yearly revenue growth and an earnings increase of about $600 million from $598.5 million today.

Uncover how Rithm Capital's forecasts yield a $13.35 fair value, a 42% upside to its current price.

Exploring Other Perspectives

RITM 1-Year Stock Price Chart
RITM 1-Year Stock Price Chart

Simply Wall St Community members have posted five fair value estimates for Rithm, ranging from US$13.35 up to US$39.08, underscoring how far apart individual views can be. When you set those against the company’s income centric story and its reliance on capital markets access, it becomes even more important to compare several perspectives before deciding how Rithm might fit into your portfolio.

Explore 5 other fair value estimates on Rithm Capital - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your Rithm Capital research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
  • Our free Rithm Capital research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Rithm Capital's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

  • Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
  • We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
  • AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.